News Column

Recent Findings from Jilin University Advance Knowledge in Osteosarcomas

February 20, 2014

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Oncology have been published. According to news reporting originating from Changchun, People's Republic of China, by NewsRx correspondents, research stated, "Osteosarcoma is a type of malignant bone tumor with high metastasis and poor prognosis. Previous studies have demonstrated the involvement of LIM kinase 1 (LIMK1) in the proliferation of osteosarcoma cells."

Our news editors obtained a quote from the research from Jilin University, "LIMK1 is overexpressed in human osteosarcoma tissues and cell lines. To further study LIMK1-associated mechanisms, we used shRNA targeted to the LIMK1 gene to block its expression in the osteosarcoma cell lines MG63 and U2OS. Insulin promoted the proliferation of MG63 cells in a time-and dose-dependent manner, however, this insulin induced proliferation was significantly inhibited by transfection of shRNA targeted to the LIMK1 gene, as well as by the PI3K inhibitor LY294002, but not by the mitogen?activated protein kinase (MAPK) inhibitor PD98059. The level of cofilin phosphorylation was increased significantly following stimulation of insulin for 24 h, indicating the activation of LIMK1. MG63 cell proliferation was also significantly inhibited by 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) in a time-dependent manner. Furthermore, 1,25(OH)2D3 negated the inhibitory effect of LIMK1 shRNA, indicating that LIMK1 is important in the inhibitory pathway of 1,25(OH)2D3."

According to the news editors, the research concluded: "The present study confirms that LIMK1 is important in regulating osteosarcoma cell proliferation via the insulin/PI3K/LIMK1 signaling pathway, thus the development of gene therapy for osteosarcoma targeting LIMK1 is warranted."

For more information on this research see: LIM kinase 1 is required for insulin?dependent cell growth of osteosarcoma cell lines. Molecular Medicine Reports, 2014;9(1):103-8 (see also Oncology).

The news editors report that additional information may be obtained by contacting H.S. Zhang, Dept. of Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, People's Taiwan. Additional authors for this research include J.W. Zhao, H. Wang, H.Y. Zhang, Q.Y. Ji, L.J. Meng, F.J. Xing, S.T. Yang and Y. Wang.

Keywords for this news article include: Asia, Biotechnology, Oncology, Changchun, Proinsulin, Lim Kinases, Orthopedics, Gene Therapy, Osteosarcoma, Bioengineering, Peptide Hormones, Phosphotransferases, Enzymes and Coenzymes, People's Republic of China, Protein Serine Threonine Kinases, Intracellular Signaling Peptides and Proteins.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Gene Therapy Weekly

Story Tools